Key insights
- The FDA granted priority review to Astellas and Pfizer's PADCEV and Keytruda combination for bladder cancer treatment, potentially expanding its use. This positive regulatory signal could modestly boost investor sentiment towards PFE and related pharmaceutical stocks, reflecting optimism about future revenue streams. However, the target action date is far out, limiting immediate market impact.
The U.S. Food and Drug Administration granted priority review to a supplemental biologics license application from Astellas Pharma Inc. (4503) and Pfizer Inc. (PFE) for expanded use of their cancer drug combination PADCEV and Keytruda, according to a company statement.
The application seeks approval for perioperative treatment of muscle-invasive bladder cancer patients regardless of cisplatin eligibility. The drug combination currently has FDA approval for cisplatin-ineligible patients with the same cancer type, granted in November 2025.
The submission is based on data from the Phase 3 EV-304 trial, which showed a 47% reduction in the risk of tumor recurrence, progression or death and a 35% reduced risk of death compared to standard chemotherapy. The trial also demonstrated a pathological complete response rate of 55.8% versus 32.5% for chemotherapy.
Under the Prescription Drug User Fee Act, the FDA set a target action date of August 17, 2026. Priority review is granted to medicines that may offer significant treatment advances or provide therapy where limited options exist.
PADCEV is an antibody-drug conjugate targeting Nectin-4 protein, while Keytruda is a PD-1 inhibitor manufactured by Merck. The combination is already approved for locally advanced or metastatic urothelial cancer in multiple countries.
Muscle-invasive bladder cancer represents approximately 30% of all bladder cancer cases. Despite curative-intent surgery, more than half of patients experience disease recurrence, highlighting the need for improved treatment strategies.